GLOX THERAPEUTICS LIMITED

Active Glasgow
6 employees website.com
Life sciences and medical technology
G

GLOX THERAPEUTICS LIMITED

Founded 27 Feb 2023 Active Glasgow, Scotland 6 employees website.com
Life sciences and medical technology
Accounts Submitted 12 Sept 2025 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 26 Mar 2026 Next due 12 Mar 2027 10 months remaining
Net assets £476K £2M 2024 year on year
Total assets £935K £2M 2024 year on year
Total Liabilities £459K £20K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

John Arbuthnott Building Strathclyde University Of Pharmacy & Biomedical 161 Cathedral Street Glasgow G4 0RE Scotland

Email

info@example.com

Website

www.example.com

Full company profile for GLOX THERAPEUTICS LIMITED (SC760230), an active life sciences and medical technology company based in Glasgow, Scotland. Incorporated 27 Feb 2023. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2023–2024)

Cash in Bank

£816.10k

Decreased by £1.56M (-66%)

Net Assets

£476.08k

Decreased by £1.59M (-77%)

Total Liabilities

£458.96k

Increased by £20.17k (+5%)

Turnover

N/A

Employees

6

Increased by 2 (+50%)

Debt Ratio

49%

Increased by 31 (+172%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 1

Investors (2)

Investor NameInvestor SinceParticipating Rounds
Investor 1Nov 2023Seed
Investor 2Nov 2023Seed

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 8,470 Shares £84.7 Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
12 Apr 20238,470£84.7£0.01

Officers

Officers

1 active 2 resigned
Status
Murray, Michael Stephen, DrDirectorScottishEngland626 Feb 2025Active

Shareholders

Shareholders (8)

Daniel Walker
22.9%
3,570
Boehringer Ingelheim Venture Fund Gmbh
19.9%
3,114

Persons with Significant Control

Persons with Significant Control (0)

0 Active 3 Ceased

G U Holdings Limited

Ceased 12 Apr 2023

Ceased

Professor Colin Kleanthous

Ceased 13 Apr 2023

Ceased

Professor Daniel Walker

Ceased 24 Oct 2023

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
26 Mar 2026Confirmation StatementConfirmation statement made on 2026-02-26 with updates
6 Nov 2025OfficersTermination of James Scott Clark as director on 2025-09-26
6 Nov 2025OfficersTermination of Niklas Czeloth as director on 2025-08-12
6 Nov 2025OfficersAppointment of Dr Paul Nicklin as director on 2025-08-12
12 Sept 2025AccountsAnnual accounts made up to 2024-12-31
26 Mar 2026 Confirmation Statement

Confirmation statement made on 2026-02-26 with updates

6 Nov 2025 Officers

Termination of James Scott Clark as director on 2025-09-26

6 Nov 2025 Officers

Termination of Niklas Czeloth as director on 2025-08-12

6 Nov 2025 Officers

Appointment of Dr Paul Nicklin as director on 2025-08-12

12 Sept 2025 Accounts

Annual accounts made up to 2024-12-31

Recent Activity

Latest Activity

Confirmation statement made on 2026-02-26 with updates

1 months ago on 26 Mar 2026

Termination of James Scott Clark as director on 2025-09-26

5 months ago on 6 Nov 2025

Termination of Niklas Czeloth as director on 2025-08-12

5 months ago on 6 Nov 2025

Appointment of Dr Paul Nicklin as director on 2025-08-12

5 months ago on 6 Nov 2025

Annual accounts made up to 2024-12-31

7 months ago on 12 Sept 2025